ReviewFrontiers in bioengineering and biotechnology2019
Overcoming Physiological Barriers to Nanoparticle Delivery-Are We There Yet?
Review in Frontiers in bioengineering and biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 127 citations in OpenAlex.
- Engineered probiotic-propelled micro-robot as biological truck for deep tumor penetration and treatment.Materials today. Bio · 2026Article
- Peptide-Enabled Nanoplatforms for Malaria and Leishmaniasis: From Intracellular Targeting to Translational Diagnostic Perspectives.ChemMedChem · 2026Review
- Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies.Cancers · 2026Review
- A PEGylated nanobody against HBsAg exhibits pleiotropic antiviral efficacy in hepatitis B models.Journal of nanobiotechnology · 2026Article
- Nanorobotic Approaches Against Multidrug-Resistant Infections: Design, Principle, Mechanistic Innovation, Translational Challenges and Biomedical Applications.Molecules (Basel, Switzerland) · 2026Review
- Exogenous CD55 Expression on Membrane-Wrapped Nanoparticles Unexpectedly Increases Spleen Tropism and Immune Cell UptakeACS nano medicine · 2026Article
- Sorafenib nanomedicine in HCC: nano-bio interactions and combination therapies.Journal of nanobiotechnology · 2026Review
- Engineered nanoparticles for endocrine tumor targeting, current progress and future outlook.Medical oncology (Northwood, London, England) · 2025Review
- Influence of the protein corona on hematopoietic stem and progenitor cell uptake and macrophage clearance of membrane-wrapped nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Astragalus polysaccharide-based nano-platforms loading PTX to boost chemo-immunotherapy for triple-negative breast cancer with intrinsic GLUT-targeting ability and immunoregulatory activity.Journal of nanobiotechnology · 2025Article
- Immunomodulatory nanoplatforms with multiple mechanisms of action in cancer treatment.Nanomedicine (London, England) · 2025Review
- Developments in nanotechnology approaches for the treatment of solid tumors.Experimental hematology & oncology · 2025Review
- Nanodrug Delivery Systems for Acute Lymphoblastic Leukemia Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Navigating a challenging path: precision disease treatment with tailored oral nano-armor-probiotics.Journal of nanobiotechnology · 2025Review
- Rapid precision targeting of nanoparticles to lung via caveolae pumping system in endothelium.Nature nanotechnology · 2025Article
- Inorganic Nanoparticles Containing Plant-Derived Compounds for Kidney Treatment.Bioinorganic chemistry and applications · 2025Review
- Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges.Expert opinion on drug discovery · 2025Review
- Drug Delivery Systems for Natural Medicines in Cancer Therapy.Current topics in medicinal chemistry · 2025Review
- Targeting the epigenome with advanced delivery strategies for epigenetic modulators.Bioengineering & translational medicine · 2025Review
- Breaking the final barrier: Evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome.Advanced drug delivery reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The exploitation of nanosized materials for the delivery of therapeutic agents is already a clinical reality and still holds unrealized potential for the treatment of a variety of diseases. This review discusses physiological barriers a nanocarrier must overcome in order to reach its target, with an emphasis on cancer nanomedicine. Stages of delivery include residence in the blood stream, passive accumulation by virtue of the enhanced permeability and retention effect, diffusion within the tumor lesion, cellular uptake, and arrival at the site of action. We also briefly outline strategies for engineering nanoparticles to more efficiently overcome these challenges: Increasing circulation half-life by shielding with hydrophilic polymers, such as PEG, the limitations of PEG and potential alternatives, targeting and controlled activation approaches. Future developments in these areas will allow us to harness the full potential of nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.